Three surveys assess Covid’s impact on our health

Three surveys published in recent weeks have gauged the impact of the Covid-19 pandemic on our dietary and supplement habits, our use of technology and our mental health. Here we present a quick survey of the findings in all three studies.

According to a survey of 13,000 people in 24 countries conducted by OnePoll on behalf of the Council for Responsible Nutrition and Herbalife Nutrition, eight in 10 US citizens believe their health is “work in progress”. Some 89% of respondents worldwide are taking steps to improve their health, with 81% reporting that the pandemic helped to kickstart them.

Vitamins and supplements are a priority for many; when asked about how their health goals have changed, half said they are more focused on eating healthier, including supplementing their diet with vitamins & minerals, with the average respondent spending around US$286 each year. However, only 69% reported feeling knowledgeable about the health benefits and 77% would like to know more. Some 30% are most likely to get information about vitamins and supplements from internet searches, media and social media, followed by consulting with their doctor (27%).

Source: OnePoll / Herbalife / CRN

According to a survey from Saudi-based cultural institute Ithra, 91% of people globally are spending more time online because of the pandemic, and 44% are worried about the impact of internet and smartphone use on their health. Respondents in Sub-Saharan Africa and South Asia appear most worried, with 74% and 56% respectively fearing the negative consequences of the internet on wellbeing vs 27% in Europe and Central Asia. Consistent with their increased use of devices, younger people are experiencing more physical symptoms than their elders, with 50% of Gen Z respondents complaining of tiredness, poor sleep and headaches.

And, finally, a study published in BJPsych Open revealed the mental health of adults aged over 50 has been significantly compromised by Covid-19. University of Surrey researchers analysed data in 5,331 participants from the English Longitudinal Study of Ageing. Self-reported depression in June and July 2020 were compared with baseline data from 2-3 years prior. Some 26% met the criteria for clinical depression during the pandemic vs 14% in previous years. Women were found to be at a much higher risk, as well as people living alone and those with long-term health conditions. Women living in an urban environment showed a larger increase in depression symptoms than those in more rural areas. The research also found that individuals at the younger end of the 50+ population suffered more.

In just 2 weeks, you can join Nicholas and a panel of industry experts at our North American e-Conference 2021Sponsored by Catalent, you can look forward to hearing about consumer shopping behaviours, the non-prescription imperative, natural channel retail world and much more. To register, or for further details, please contact elizabeth.bernos@NicholasHall.com.

ADM Survey: Behaviour Shifts Create CHC Opportunities

Some 60% of consumers plan to improve their overall health & wellness in the next 12 months, according to Archer-Daniels-Midland (ADM), which transforms natural products into ingredients and flavours for foods & beverages, supplements, pet nutrition and more. There is also a more proactive approach to managing wellbeing with functional nutrition, close-to-nature ingredients and foods that signal self-care. ADM has identified five behaviour shifts that are creating opportunities for manufacturers to support evolving needs:

  • Renewed motivation to improve individual health & wellness Pandemic experiences have varied across the globe, but an almost universal takeaway is the renewed focus on preventive health & wellness behaviours. Products designed for all life stages will help consumers protect themselves, their families and their communities
  • Holistic approach to managing mind-body connection 51% of consumers plan to improve their cognitive and mental health over the next 12 months. As we return to more active lifestyles, convenient products with functional ingredients that boost energy, enhance cognitive performance & regulate mood are gaining prominence
  • Tailored nutrition supports personal health & wellness goals Nearly two-thirds of consumers are interested in customised foods & beverages. A greater understanding of how diet can impact health is spurring more people to choose wholesome, nutrient-dense ingredients, with particular focus on fibre & protein. As the chart below from our CHC New Products Tracker database indicates, the number of new personalised VMS products launched has grown sharply in recent years
  • Proactive perspective on immunity With 65% of consumers more concerned about immunity, there is a shift from a defensive to a more proactive & holistic approach. People are looking for ways to incorporate immune function-supporting solutions like probiotics and vitamins C & D into their daily lives. Products with functional ingredients that support a healthy immune system will increasingly attract consumer attention
  • Purposeful indulgence new “permissible indulgence” During the pandemic, many people have given themselves permission to consume indulgent food & beverages as a form of self-care. Consumers are recognising that, as long as these are purposeful — not impulsive — choices, indulgence has a role in a positive relationship with food

Nicholas Hall’s Touchpoints: The ADM research tells us nothing we didn’t know already, but as always it’s good to put numbers to the various consumer trends, and to be reassured that these trends continue as we head towards the second anniversary of this shocking pandemic. The same is true of the birth rate data in our second lead story. At the outset of Covid-19, with the expectation that a large part of the world’s population would spend much more time at home, we all assumed that the birth rate would go up, which is the reverse of what actually happened. As The Consumer remains at the centre of our industry, we are well advised to take seriously behavioural trends such as these as we shape future strategies and return to the New Normal. A longer-term trend underpins our third lead story this week, with Catalent’s acquisition of one of the leading manufacturers of gummies, a delivery system popular with adults as well as children that has taken the US market by storm and which is poised to do the same in the rest of the world.

You can save with the early bird booking discount when you register to attend our APAC e-Conference 2021 before 21 September! Taking place on 23 November, join Nicholas and the team to Face the Future together. Stay tuned for new additions to the agenda! Plus, this event will also host the Nicholas Hall CHC Marketing Awards for the region. To find out more about the conference, entry submission criteria, or to book your place, please contact elizabeth.bernos@NicholasHall.com.

Kerry survey highlights growing interest in probiotics

Demand for probiotics is growing as digestive health moves up the consumer agenda, according to a survey conducted by Irish taste and nutrition company Kerry. The company surveyed 13,000+ consumers across 16 countries. Almost half (47%) of those questioned were aware of probiotics or cultures, up from 42% in 2019 when the survey was last conducted. Awareness was particularly high in Latin America (63%) and North America (61%). One in four respondents (25%) had used a product containing probiotics in the past six months, up from 21% in 2019; a further 44% said they would consider doing so vs 40% in 2019. Probiotic use in the past six months was especially high in China (49% of respondents), followed by Mexico (42%). Digestive Health was ranked third on the list of reasons to purchase healthy lifestyle products, up from fourth in 2019.

Writing in CHC.Newsflash, Nicholas Hall said this story is a welcome reminder that probiotics remains one of the most attractive categories in consumer healthcare, despite flat sales during Covid. As Kerry VP John Quilter points out: “Demographic changes, such as population ageing and lifestyle choices, have increased the prevalence of digestive disorders, while the pandemic has accelerated the shift towards more proactive approaches to health. As a result, consumers [are] increasingly well educated about the role of probiotics and their ability to support both digestive health and overall wellness.”

Nicholas commented further: “Our industry is receiving this message loud and clear, to judge by the large number of probiotic new products. Indeed, it’s highly instructive to look at the very large number of new CHC products launched in 2020 as measured by our Tracker. There were three standout categories: probiotics, CBD and – no surprises – immune supplements. These categories recorded around 250-300 launches each, substantially ahead of multivitamins, antiseptics & disinfectants and sedatives & sleep aids. The impact of Covid is written all over this data, but despite the disruption in purchasing habits, marketer perception of unmet consumer demand is clear, with probiotics and CBD very much front of mind.

As I’ve written before, I see probiotics as a three-stage process: entry level, using well-known strains with a gut-health positioning; first stage development, embracing new indications such as immunity and women’s health, but still using existing strains and combinations; and the far stage, with exciting new indications including metabolic reconditioning, and completely new strains. At present we are about a third of the way into the second stage, with lots of new probiotics coming to market. But what we lack is clinical evidence with large sample sizes from research centres with unimpeachable credentials, sufficient to persuade, for example, the Doubting Dr Thomases at the European Food Standards Authority to allow claims or even the use of the word “probiotic” on packaging. With a number of heavy hitters from the supply chain – such as Kerry – being attracted to probiotics, I’m confident that we are only a few years away from the Promised Land.

Take the opportunity to save up to GB£2,100 when you pre-order our forthcoming Immunity hot topic report before 31 August! This essential report will review a number of categories including antivirals, immune supplements and vitamins C & D, and explores the latest launch activity, plus much more. To pre-order your copy with the pre-publication discount, or to find out more, please contact melissa.lee@NicholasHall.com.

FDA rejects two NDI notifications for CBD products

The US FDA has rejected two New Dietary Ingredient (NDI) notifications for CBD as a dietary supplement. The ingredients submitted by both applicants – Charlotte’s Web and Irwin Naturals – were described as “full-spectrum hemp extracts”. FDA rejected the filings on the basis that CBD is the active ingredient in an approved drug (GW Pharmaceutical’s Epidiolex) and because the companies failed to provide sufficient scientific evidence to substantiate their submissions. In objection letters to Charlotte’s Web and Irwin Naturals, the agency said full-spectrum hemp extracts containing CBD “may not be marketed as or in a dietary supplement”.

According to CRN President & CEO Steve Mister, CBD regulation and mandatory product listing are the most important supplement-related issues pending for the VMS industry on Capitol Hill, as revealed in a recent panel interview organised by Nutrition Industry Executive as part of “Turning Point: Washington and the State of the Natural Products Industry“.

Mister also stated in a recent CRN press release that: “Despite very clear direction from Congress when it removed hemp from the Controlled Substances Act in 2018, FDA seems to have made up its mind not to support CBD in supplements and is now trying to justify it. That’s the only logical conclusion to draw from FDA’s actions – and its continued inaction … CRN has publicly endorsed HR 841, the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021 and is actively lobbying Congress to do what FDA has refused to do – create a legal pathway to market CBD as a dietary supplement.”

Source: CHC New Products Tracker

Nicholas Hall commented: It was Lenin who spoke of taking “one step forward, two steps back”. Those of us with a less revolutionary nature aim for a more positive journey, with only the occasional backward glance! But regardless of the number of steps in either direction, the news that the FDA has rejected two important dietary supplement notifications for CBD seems highly retrograde. I fully endorse the view of the Council for Responsible Nutrition, which has denounced the FDA decision and urged Congress to act.

In CRN’s view, the FDA has mischaracterised these products as being the same as prescription CBD drugs and has “ignored, dismissed and downplayed ample evidence” that hemp products can be marketed safely. This seems like a re-run of the FDA’s inability to deal with the whole dietary supplements sector many years ago, which ultimately led to Congress’s stepping in with the all-important DSHEA legislation under which supplements are now regulated with a very light touch.

Review the latest new CBD products with CHC New Products Tracker. This ultimate competitive intelligence tool features 30,000+ launches and innovations, and products graded with a star rating. To set up your free demo, or to find out more, please contact waisan.lee@NicholasHall.com.

Q2 Results Round-up: Prestige, Bausch Health

Among the latest Q2 2021 results announced in the past week, two global Top 20 CHC companies – Prestige Consumer Healthcare (ranked No. 14) and Bausch Health (ranked No. 16) – reported strong performances. There was also dynamic Q2 growth reported by DSM Nutrition, Beiersdorf and several other marketers, pointing again to a strong recovery for the global CHC market in the second quarter of the year.

Prestige Consumer Healthcare revenues grew by 17.3% in fiscal Q1 2022 (1 Apr-30 Jun 2021) to US$269mn, the second highest level in the company’s history.

  • North America OTC Healthcare sales were US$242mn vs US$211mn in the comparable quarter. This was driven by a strong performance across a majority of key brands vs their respective categories and increased demand in certain Covid-impacted categories such as motion sickness and travel-related channel
  • International OTC Healthcare sales totalled US$26.8mn vs US$18.7mn. The increase related primarily to a rise in consumer activity in Australia, which drove a sharp spike in demand for Hydralyte and other brands disrupted by the pandemic, along with a foreign currency benefit of around US$2mn

Comment from CEO, Ron Lombardi: While the strong performance was partially attributable to lapping an unusual prior year period, the attributes of our leading brands and our continued market share gains over the past 12 months have us well positioned to benefit as consumer habits continue to shift and evolve. This leaves us well positioned to anticipate continued market share, revenue and earnings growth in the remainder of the year. In addition, we anticipate TheraTears and other brands, acquired [from Akorn] on 1st July 2021, to add incremental revenue and earnings to our base business momentum.

Source: Bausch Health.

Bausch Health reported a 26% rise in revenues (+23% both at constant currency and organically) in Q2 2021 to C$2.1bn (US$1.7bn), primarily owing to higher volumes resulting from the recovery from the pandemic. Eye health business Bausch + Lomb reported a 38% rise in revenues (+3% organically) to C$934mn (US$748mn). Within that, Global Consumer Products was up by 9% on an organic basis to C$341mn (US$273mn), with the US Consumer business up 20% driven by Ocuvite and PreserVision eye vitamins, coupled with the strong Lumify performance. Bausch reported that its share of the US eye vitamin category has grown from 75.6% in Q2 2020 to 77.9% in Q2 2021. The International Consumer business declined by 2%, mainly owing to the recall of a multi-purpose solution in Europe because of a quality issue at a third-party supplier.

While Global Consumer Products, which will be spun off with Bausch + Lomb into a separate business, showed healthy growth, it was slower than all other divisions. In an earnings call, Chairman & CEO Joseph Papa noted that the company, which is “dedicated to unlocking value for shareholders”, was making “good progress” with the spin off and had filed an S-1 with the US Securities & Exchange Commission. The company also announced that it would pursue an initial public offering for Solta Medical. This will result in the creation of Bausch + Lomb, a pure-play, integrated eye health company; Bausch Pharma, a global diversified pharmaceuticals business; and Solta Medical, a leading global provider in medical aesthetics.

We are pleased to announce that our APAC e-Conference 2021 will take place on 23 November! Join Nicholas and the team to Face the Future together. With speakers and sessions being added to the agenda soon, watch this space. To register, or to find out more, please contact elizabeth.bernos@NicholasHall.com.

Sanofi results point to strong CHC rebound in Q2

Sanofi has raised its full year 2021 EPS guidance after reporting a 12.4% rise in sales (at constant exchange rates) in Q2 2021 to €8.7bn (US$10.3bn). Consumer Healthcare sales increased by 11.9% to €1.1bn (US$1.3bn), primarily reflecting a low base for comparison in the same period last year, as well as a strong performance of Digestive Wellness and Pain Care. This largely offset a weak cough & cold season.

Sales in USA increased by 12.5% to €287mn (US$341mn); Europe rose by 7.7% to €319mn (US$379mn); and Rest of the World was up 14.3% to €483mn (US$573mn). Digestive Wellness growth (+36.8%) was powered by strong performances from probiotic Enterogermina, antispasmodic Buscopan, laxative Dulcolax and liver care treatment Essentiale. Mental Wellness (+23.9%) and Pain Care (+20.6%) also generated high CHC growth for Sanofi in Q2, while other categories were either flat or declining.

Source: Sanofi

Nicholas Hall commented: I wrote last week that the first Q2 results were highly encouraging, but that we needed to wait for the other top players to report. This week we review a crop of additional results, and they do indeed confirm that sales are significantly ahead of Q2 2020; but it is noticeable that the latest reports are consistent in reminding us that sales in Q2 2020 were relatively weak, although consumer purchases remained strong. The real comparison is with Q2 2019, measured against which growth is much more modest, in the range of 3% CAGR. This managing of expectations is perfectly understandable as none of the companies wants to create aspirations that will be difficult to meet later on.

So how do we interpret this data from the top players? On the one hand, it’s disappointing as 3% is below the 4.1% benchmark we’ve created to judge market growth – a combination of population increase and inflation. On the other hand, the industry has come through its worst crisis in a generation, and although a lot of attention has been paid to the high-growth categories of immunity and disinfection, many more categories were adversely affected. Furthermore, we know that not all the top players are representative as typically they underperform the market, with the highest growth typically coming from local and regional players.

My take on this, combined with the upturn in our own business I outlined last week, is that we are feeling our way forward to a revival in consumer demand and indeed industry confidence. But there is a lot of lost time and opportunity to make up, and it does seem that the top echelon of the industry is responding by adapting its structure (for example, the spin-off of GSK Consumer) or streamlining the business – Sanofi, for example, has disposed of a number of tail brands, either by divestiture or creating new distribution arrangements.

Find the perfect candidate to complete your team with assistance from Nicholas Hall’s executive recruitment service CHC TalentSelect. With over 40 years’ experience in consumer healthcare and an extensive network of contacts, we can help you find the right person for the job. To start your search, please contact maricar.montero@NicholasHall.com.

Global CHC Market Movers, MAT Q1 2021

We have now published our latest Market Movers update on the CHC Dashboard website, highlighting 6 brands that have been driving growth in the global CHC market in the MAT Q1 2021 period, as well as 6 brands in fast decline, and below we look at the trends behind these exceptional brand performances.

Given that antiseptics & disinfectants were by far the biggest growth driver in the global CHC market in MAT Q1 2021, it’s no surprise that two of the six fastest-growing brands were hand sanitisers, Unilever’s Suave and ArtNaturals (ArtNaturals). Both were standout performers in the US market among a raft of new entries in the vibrant subcategory.

Rx-to-OTC switch has also been an important growth driver, with GSK’s May 2020 launch of topical analgesic Voltaren Arthritis Pain the notable development, generating sales in excess of US$100mn in under a year on the market. Former switch brand Plan B One-Step also performed exceptionally well in MAT Q1 2021, owing to limited access to prescribed contraception and family planning clinics during the pandemic. Foundation Consumer Healthcare also backed the brand with TV ads explaining it does not affect future fertility.

In China, the two fastest-growing CHC brands were Mayinglong Musk, a haemorrhoid preparation extended into new subcategories thanks to product innovation, and Fu Fang E Jiao Jiang, which marketer Dong-e E-jiao Group revived by returning to a policy of targeting general (not just high-end) consumers, helping ensure a return to growth overall for tonics & cure alls in China.

As for products that suffered falling sales in MAT Q1 2021, the clear majority (4 out of 6) were CCA brands, given the historically weak cough & cold season experienced by the industry in the first quarter of this year. Global No.1 brand Vicks posted further heavy decline in Q1, with MAT Q1 2021 sales falling by 24.5%; combo packs of Vicks NyQuil / DayQuil packs fell particularly hard (-54%).

Reckitt’s systemic cold & flu treatment Mucinex Fast-Max and cough remedy Delsym also suffered heavy decline in MAT Q1 2021, as did Taisho’s cold remedy Pabron in Japan, which was hit by the downturn for domestic and inbound channels attributable to Covid-related issues.

We are pleased to announce that Nicholas Hall’s North American e-Conference 2021 will take place on 21 September! Sponsored by Catalent, Nicholas will be joined by industry experts to explore Challenger Brands & Key Pillars to the New / Modern Marketing World. To register, or to find out more, please contact elizabeth.bernos@NicholasHall.com.

Seasonal respiratory viruses re-emerge post-Covid

Recent reports from the UK and USA suggest a severe cold & flu season may be in store during winter 2021-22. With lockdown restrictions, increased hygiene measures and social distancing in force for over a year to reduce the risk of contracting Covid-19, the incidence of common respiratory viruses has been very low. However, with the lack of exposure to illnesses (especially among young children), many of us have not built up antibodies and as a result our immune systems may have been inadvertently weakened.

This has prompted warnings of a potential surge in influenza as measures are lifted; data released this week by the UK’s Office of National Statistics show that in the week ending 11th June, 84 death certificates issued in England & Wales mentioned Covid, while 1,163 deaths involving flu and pneumonia were registered. Additionally, a recent study by the Houston Methodist Research Institute shows the rapid re-emergence of seasonal respiratory viruses following the relaxing of Covid-19 restrictions in Texas in March 2021.

This trend was also reported in a recent article in STAT, in which Trevor Bedford, a computational biologist who monitors which viruses are circulating via the Nextstrain service, was quoted as saying: “Just in the last month [May 2021] or so we’ve started to pick up small amounts of seasonal coronavirus, RSV, metapneumovirus, etc. It’s the first time since April 2020 where we’re starting to see other things circulating.”

There is particular concern that by the time universities, colleges, schools and nurseries reopen this autumn across the northern hemisphere, there will be perfect conditions for high transmission of seasonal respiratory viruses, particularly RSV (respiratory syncytial virus). Andrew Pavia, Chief of the Division of Pediatric Infectious Diseases at the University of Utah, warned: “There will be two years’ worth of kids who are naïve to RSV, instead of one birth cohort. That could be fertile ground for a big RSV year.”

Epidemiologist Professor Neil Ferguson of Imperial College, a member of the UK Government’s Scientific Advisory Group for Emergencies, said in a BBC interview that we must be prepared for a potentially “quite significant” flu epidemic and increased hospitalisations this winter. To help save National Health Service resources, researchers are investigating whether seasonal flu jabs and a Covid vaccine can be administered at the same time.

We are pleased to announce that our Eye Health report is now published and available to order! You can review case studies of key brands, NPD activity and much more. Plus, ensure you have registered for the free webinar on 30 June here to discuss the topline findings. For more information, please contact melissa.lee@NicholasHall.com.

Stada Health Report 2021

According to the third Stada Health Report, a representative survey of 30,000 participants in 15 European countries, 29% have suffered from increased levels of anxiety during the pandemic, while 25% are troubled by stress and inner restlessness and 15% have reported sleep disturbances. Some 52% of respondents are more affected by the lack of personal contact with family & friends than fear of Covid infection (42%), while almost 1 in 3 worries about the financial and work-related repercussions.

However, 70% of Europeans have been willing to invest more in their own health. For 73%, their doctor is the first point of call for all health-related issues, with pharmacists and scientists also highly trusted (60% each). Despite a 14 percentage-point increase in people purchasing medication online, 43% stay loyal to community pharmacies, 13% of which specifically single out their local branch. Europeans care more about brand names and what is associated with them (38%) rather than sustainable & environmentally-friendly packaging (25%) or whether a product was made in Europe (20%).

In the report, Stada asks the question, “With an increased interest in and an aspiration to healthy living, how did people in Europe procure information on these topics? The short answer is: The internet. 54% of Europeans have increased their online searches for health-related information compared to previous years.” However, this spike in online health searches and literacy has not automatically translated into European consumers looking to bypass their pharmacist when acquiring medication, or information about it. According to Stada’s survey, only 14% of Europeans have ordered more OTC medicines via online pharmacies post-pandemic, and 43% flat out refuse to order them online at all. Despite the ever increasing number of e-Commerce platforms and other channels for obtaining medicines online, community pharmacies are still Europe’s first choice for OTCs.

Nicholas Hall’s Touchpoints: The Stada report quoted above is further evidence that increased levels of stress and anxiety, and disrupted sleep, are by-products of Covid. Insomnia was already considered a pandemic in the Western world by the World Health Organization; and sleep, stress and mood have joined immunity and disinfection as categories with rocketing sales in the past two years … The theme continues in the latest Gallup survey, which notes the high incidence of “worry, stress, anger and sadness among employees worldwide”. It seems that substantial numbers of office workers are refusing to go back to work in the traditional way and are insisting on continuing to work from home … This localisation of labour will almost certainly change our concept of shopping and could benefit independent neighbourhood pharmacies, giving a whole new meaning to the concept of Pharmacy Point-of-Care. It’s too soon to draw definite conclusions, but consumer healthcare companies would do well to re-examine their sales force objectives. One of the most successful modules of the CHC Training Academy is “Winning in Pharmacy”, and I can see this being even more popular as we come out of the Covid lockdown.

To find out more about Winning in Pharmacy, or the offerings from The CHC Training Academy, please contact maricar.montero@NicholasHall.com. The CHC Training Academy can also work with you to develop your own in-house customised training programmes according to your specific strategic needs.

AESGP 57th Annual Meeting Review

From CHC Insight Europe Editor, Sarah Carter, who reports that the AESGP sees a brilliant future for self-care, but that the industry must continue to adapt.

Focusing on self-care in times of the pandemic and beyond, the 57th AESGP Annual Meeting discussed opportunities, challenges and lessons learnt. While the pandemic has caused significant disruption and altered behaviours, priorities and shopping habits, it has driven a surge in interest in self-care, with consumers increasingly looking to stay well and prevent illness. Birgit Schuhbauer, who has just been re-elected as AESGP President for the next two years, stated that the CHC industry has a “brilliant future ahead of us”.

The CHC industry has had to adapt to this changing landscape, although a number of speakers stressed that it must do so at a quicker pace as technology and evolving consumer demands continue to disrupt the traditional self-care model. AESGP Director General Jurate Svarcaite concluded that there is no going back to the old model, stressing that the “new normal” requires collaboration and partnership.

Speakers also touched upon the infodemic and the increasing consumer appetite for instant information, which European Medicines Agency Executive Director Emer Cooke said was difficult to manage when you try to have a “sound scientific basis for what you communicate”. However, the worrying spread of misinformation and disinformation means that increased and better communication is vital.

The Annual Meeting coincided with the long-awaited implementation of the new EU Medical Device Regulation; participants shared their excitement and optimism at the development and celebrated how much work had been done, but were keen to stress there remains a way to go, particularly in terms of harmonisation across Europe and the capacity of notified bodies.

There is still time to register for our free webinar on 30 June discussing the topline conclusions from our upcoming report on Eye Health! With no purchase necessary, you can register directly for the webinar here. For more information, please contact melissa.lee@NicholasHall.com.